Loading…
Valiant Laboratories (VALIANTLAB)₹111.51−2.00%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Valiant Laboratories reported sales of ₹115 Cr, up 145.0% from Jun 2025, and net profit of ₹21.01 Cr, up 945.3% year on year. For the year to Mar 2026, sales were ₹237 Cr and net profit −₹3.01 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59.99 | 40.99 | 30.98 | 19.01 | 20.99 | 34.97 | 57.98 | 46.98 | 45.98 | 52.02 | 92.05 | 115 |
| Expenses | 60.99 | 47.01 | 35.01 | 21.01 | 28.02 | 35.01 | 53.99 | 44.05 | 46.04 | 53.01 | 86.99 | 86.10 |
| Operating Profit | −0.99 | −5.99 | −4.99 | −1.99 | −6.99 | 0.99 | 3.99 | 2.01 | 0.00 | −0.99 | 4.99 | 28.98 |
| OPM % | −2.3% | −16.0% | −15.0% | −13.0% | −31.0% | 1.8% | 7.0% | 5.0% | 0.2% | −1.7% | 5.0% | 25.0% |
| Other Income | 3.01 | 2.01 | 2.01 | 3.01 | 3.01 | 2.01 | −2.01 | 1.01 | 1.01 | 1.01 | 0.00 | 1.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 |
| Depreciation | 0.00 | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 2.99 | 2.99 |
| Profit before tax | 0.99 | −4.99 | −2.99 | 0.00 | −3.99 | 1.99 | 0.99 | 1.99 | 0.00 | −2.99 | 0.99 | 25.99 |
| Tax % | 24.9% | −31.0% | −52.0% | 219.0% | 21.0% | −44.1% | 26.0% | 26.0% | 25.0% | 136.0% | −68.0% | 18.9% |
| Net Profit | 1.01 | −4.01 | −1.01 | −1.01 | −5.01 | 2.01 | 1.01 | 2.01 | 0.00 | −7.01 | 2.01 | 21.01 |
| EPS (Rs) | 0.20 | −0.65 | −0.24 | −0.10 | −0.88 | 0.44 | 0.14 | 0.35 | 0.05 | −1.31 | 0.33 | 3.89 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 334 | 182 | 133 | 237 | 305 |
| Expenses | 299 | 190 | 138 | 231 | 272 |
| Operating Profit | 34.99 | −7.99 | −4.99 | 5.99 | 32.98 |
| OPM % | 11.0% | −4.6% | −3.5% | 2.7% | 10.8% |
| Other Income | 5.02 | 10.03 | 5.01 | 2.01 | 3.03 |
| Interest | 0.00 | 0.00 | 0.00 | 1.99 | 2.97 |
| Depreciation | 1.99 | 1.99 | 1.99 | 5.98 | 8.96 |
| Profit before tax | 37.97 | −0.99 | −1.99 | 0.99 | 23.99 |
| Tax % | 24.0% | −142.0% | 46.0% | 525.0% | — |
| Exceptional items | 0.00 | 3.19 | 1.15 | 0.00 | — |
| Net Profit | 29.04 | 0.00 | −2.01 | −3.01 | 16.01 |
| EPS (Rs) | 7.14 | 0.07 | −0.42 | −0.61 | 2.96 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 32.98 | 43.04 | 43.05 | 53.99 |
| Reserves | 68.04 | 193 | 191 | 257 |
| Borrowings | 60.15 | 77.18 | 122 | 46.10 |
| Other Liabilities | 52.03 | 29.14 | 45.22 | 107 |
| Total Liabilities | 213 | 344 | 402 | 465 |
| Fixed Assets | 48.03 | 50.03 | 48.01 | 227 |
| CWIP | 1.01 | 43.09 | 156 | 6.01 |
| Investments | 33.95 | 37.99 | 0.00 | 27.99 |
| Other Assets | 130 | 213 | 198 | 203 |
| Inventories | 13.01 | 10.01 | 3.99 | 45.01 |
| Trade receivables | 88.90 | 45.97 | 71.96 | 93.95 |
| Cash & equivalents | 0.99 | 106 | 75.97 | 7.01 |
| Total Assets | 213 | 344 | 402 | 465 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | 56.22 | 2.01 | 1.01 | −10.04 |
| Cash from investing activity | −54.92 | −144 | −52.93 | 6.98 |
| Cash from financing activity | −1.01 | 153 | 45.17 | 2.01 |
| Net cash flow | 0.00 | 9.99 | −6.99 | −1.01 |
| Capex | 38.01 | 46.08 | 114 | 34.03 |
| Free cash flow | 18.06 | −44.13 | −112 | −45.15 |
| CFO / OP % | 185.1% | −10.9% | 25.1% | −147.0% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 98 | 93 | 198 | 145 |
| Inventory days | 17 | 22 | 13 | 84 |
| Days payable | 62 | 56 | 128 | 174 |
| Cash conversion cycle | 53 | 58 | 83 | 55 |
| Working capital days | 69 | 105 | 155 | 155 |
| ROCE % | — | −2.0% | −1.0% | 1.0% |
For the Jun 2026 quarter, Valiant Laboratories reported sales of ₹115 Cr, up 145.0% year on year and net profit of ₹21.01 Cr, up 945.3% year on year. The operating margin was 25.0%.
Valiant Laboratories' sales for the year to Mar 2026 were ₹237 Cr; over the last twelve months they were ₹305 Cr.
Net profit for the year to Mar 2026 was −₹3.01 Cr, and ₹16.01 Cr over the last twelve months. Earnings per share over the same trailing period were ₹2.96.
Valiant Laboratories reported borrowings of ₹46.10 Cr at Mar 2026, against cash and equivalents of ₹7.01 Cr.
Cash from operations was −₹10.04 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹45.15 Cr.